Business
Admission of Firm Placing Shares
Admission of Firm Placing Shares.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 7361A\n Oxford Biomedica PLC\n 04 February 2022\n \n \n \n \n 4 February 2022 \n \n \n THIS ANNOUNCEMENT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.\n \n \n FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN OXFORD BIOMEDICA PLC OR ANY OTHER ENTITY IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR THE FACT OF ITS DISTRIBUTION SHALL FORM THE BASIS OF, OR BE RELIED ON IN CONNECTION WITH, ANY INVESTMENT DECISION IN RESPECT OF OXFORD BIOMEDICA PLC.\n \n \n \n LEI: \n \n 213800S1GVQNXQ15K851\n \n \n \n \n \n OXFORD BIOMEDICA PLC\n \n \n (\"Oxford Biomedica\" or the \"Company\")\n \n \n Admission of Firm Placing Shares\n \n \n Oxford, UK - 4 February 2022: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, confirms that 4,858,410 new ordinary shares (the \"Firm Placing Shares\") have this morning been admitted to the premium listing segment of the Official List (the \"Official List\") of the Financial Conduct Authority (the \"FCA\") and to trading on the main market for listed securities of London Stock Exchange plc (the \"London Stock Exchange\").\n \n \n The Firm Placing Shares were subscribed for at an issue price of 810 pence per share and have raised gross proceeds of circa £39.4 million for the Company and represent 5.6% of the Company's issued share capital as at the last practicable date prior to announcement of the Placing and the Transaction on 28 January 2022. \n \n \n The conditional allocation of 5,018,134 new ordinary shares in the Company (the \"Conditional Placing Shares\") remains conditional upon, inter alia, (i) shareholder approval at a general meeting of the Company of the issue of the Conditional Placing Shares on a non-pre-emptive basis, (ii) completion of the Transaction and (iii) admission to the premium listing segment of the Official List of the FCA and admission to trading on the main market for listed securit...